Open Access

[Retracted] Lidocaine inhibits the progression of retinoblastoma in vitro and in vivo by modulating the miR‑520a‑3p/EGFR axis

  • Authors:
    • Weiyi Xia
    • Libo Wang
    • Dongyi Yu
    • Xing Mu
    • Xin Zhou
  • View Affiliations

  • Published online on: September 1, 2025     https://doi.org/10.3892/mmr.2025.13669
  • Article Number: 304
  • Copyright : © Xia et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Related Articles

Journal Cover

November-2025
Volume 32 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xia W, Wang L, Yu D, Mu X and Zhou X: [Retracted] Lidocaine inhibits the progression of retinoblastoma <em>in vitro</em> and <em>in vivo</em> by modulating the miR‑520a‑3p/EGFR axis. Mol Med Rep 32: 304, 2025.
APA
Xia, W., Wang, L., Yu, D., Mu, X., & Zhou, X. (2025). [Retracted] Lidocaine inhibits the progression of retinoblastoma <em>in vitro</em> and <em>in vivo</em> by modulating the miR‑520a‑3p/EGFR axis. Molecular Medicine Reports, 32, 304. https://doi.org/10.3892/mmr.2025.13669
MLA
Xia, W., Wang, L., Yu, D., Mu, X., Zhou, X."[Retracted] Lidocaine inhibits the progression of retinoblastoma <em>in vitro</em> and <em>in vivo</em> by modulating the miR‑520a‑3p/EGFR axis". Molecular Medicine Reports 32.5 (2025): 304.
Chicago
Xia, W., Wang, L., Yu, D., Mu, X., Zhou, X."[Retracted] Lidocaine inhibits the progression of retinoblastoma <em>in vitro</em> and <em>in vivo</em> by modulating the miR‑520a‑3p/EGFR axis". Molecular Medicine Reports 32, no. 5 (2025): 304. https://doi.org/10.3892/mmr.2025.13669